Foster A C, Fagg G E
Eur J Pharmacol. 1987 Jan 20;133(3):291-300. doi: 10.1016/0014-2999(87)90025-2.
L-[3H]Glutamate, D-[3H]aspartate, DL-[3H]2-amino-5-phosphonovalerate (AP5) and [3H]N-methyl-D-aspartate (NMDA) were evaluated as radioligands using postsynaptic density (PSD) preparations from rat brain. L[3H]Glutamate had the highest affinity and greatest percentage specific binding, followed by D-[3H]aspartate greater than DL-[3H]AP5 greater than [3H]NMDA. The pharmacological specificity of the binding of each radioligand indicated an interaction with NMDA-preferring receptors, the order of potency of displacing compounds tested being L-glutamate greater than D-aspartate greater than D-AP5 greater than DL-AP5 greater than ibotenate greater than NMDLA greater than quisqualate. For L-[3H]glutamate, the data revealed an interaction with two sites, the major one having NMDA receptor characteristics and the minor one resembling the quisqualate-preferring receptor. Against L-[3H]glutamate binding, quisqualate showed a two-component inhibition profile with an affinity of 25 microM at the NMDA site and 0.19 microM at the quisqualate site. Thus, by using several radioligands possessing activity at NMDA receptors, we confirm that an NMDA receptor binding site is present in crude PSDs. Although it is less selective than D-[3H]aspartate, DL-[3H]AP5 and [3H]NMDA, L-[3H]glutamate remains, by virtue of its high affinity, the ligand of choice for the study of NMDA receptors in preparations where such sites predominate.
使用大鼠脑的突触后致密部(PSD)制剂,对L-[3H]谷氨酸、D-[3H]天冬氨酸、DL-[3H]2-氨基-5-膦酸戊酸(AP5)和[3H]N-甲基-D-天冬氨酸(NMDA)作为放射性配体进行了评估。L-[3H]谷氨酸具有最高的亲和力和最大的特异性结合百分比,其次是D-[3H]天冬氨酸大于DL-[3H]AP5大于[3H]NMDA。每种放射性配体结合的药理学特异性表明其与优先选择NMDA的受体相互作用,所测试的取代化合物的效力顺序为L-谷氨酸大于D-天冬氨酸大于D-AP5大于DL-AP5大于鹅膏蕈氨酸大于NMDLA大于喹啉酸。对于L-[3H]谷氨酸,数据显示其与两个位点相互作用,主要位点具有NMDA受体特征,次要位点类似于优先选择喹啉酸的受体。针对L-[3H]谷氨酸结合,喹啉酸表现出双组分抑制曲线,在NMDA位点的亲和力为25μM,在喹啉酸位点的亲和力为0.19μM。因此,通过使用几种在NMDA受体上具有活性的放射性配体,我们证实了在粗制PSD中存在NMDA受体结合位点。尽管L-[3H]谷氨酸的选择性不如D-[3H]天冬氨酸、DL-[3H]AP5和[3H]NMDA,但由于其高亲和力,它仍然是在这些位点占主导的制剂中研究NMDA受体的首选配体。